457 related articles for article (PubMed ID: 33141341)
1. Consensus Guidelines: Best Practices for Detection, Assessment and Management of Suspected Acute Drug-Induced Liver Injury During Clinical Trials in Adults with Chronic Viral Hepatitis and Adults with Cirrhosis Secondary to Hepatitis B, C and Nonalcoholic Steatohepatitis.
Treem WR; Palmer M; Lonjon-Domanec I; Seekins D; Dimick-Santos L; Avigan MI; Marcinak JF; Dash A; Regev A; Maller E; Patwardhan M; Lewis JH; Rockey DC; Di Bisceglie AM; Freston JW; Andrade RJ; Chalasani N
Drug Saf; 2021 Feb; 44(2):133-165. PubMed ID: 33141341
[TBL] [Abstract][Full Text] [Related]
2. Consensus: guidelines: best practices for detection, assessment and management of suspected acute drug-induced liver injury during clinical trials in patients with nonalcoholic steatohepatitis.
Regev A; Palmer M; Avigan MI; Dimick-Santos L; Treem WR; Marcinak JF; Seekins D; Krishna G; Anania FA; Freston JW; Lewis JH; Sanyal AJ; Chalasani N
Aliment Pharmacol Ther; 2019 Mar; 49(6):702-713. PubMed ID: 30761572
[TBL] [Abstract][Full Text] [Related]
3. Consensus guidelines: best practices for detection, assessment and management of suspected acute drug-induced liver injury occurring during clinical trials in adults with chronic cholestatic liver disease.
Palmer M; Regev A; Lindor K; Avigan MI; Dimick-Santos L; Treem W; Marcinak JF; Lewis JH; Anania FA; Seekins D; Shneider BL; Chalasani N
Aliment Pharmacol Ther; 2020 Jan; 51(1):90-109. PubMed ID: 31762074
[TBL] [Abstract][Full Text] [Related]
4. Spontaneous Fluctuations in Liver Biochemistries in Patients with Compensated NASH Cirrhosis: Implications for Drug Hepatotoxicity Monitoring.
Shamseddeen H; Vilar-Gomez E; Chalasani N; Myers RP; Subramanian GM; Shlevin HH; Allgood AE; Orman ES
Drug Saf; 2020 Mar; 43(3):281-290. PubMed ID: 31907854
[TBL] [Abstract][Full Text] [Related]
5. NIH Consensus Statement on Management of Hepatitis C: 2002.
NIH Consens State Sci Statements; 2002 Jun 10-12; 19(3):1-46. PubMed ID: 14768714
[TBL] [Abstract][Full Text] [Related]
6. Importance of Hepatitis C Virus RNA Testing in Patients with Suspected Drug-Induced Liver Injury.
Ahmad J; Reddy KR; Tillmann HL; Hayashi PH; Chalasani N; Fontana RJ; Navarro VJ; Stolz A; Barnhart H; Cloherty GA; Hoofnagle JH
Dig Dis Sci; 2019 Sep; 64(9):2645-2652. PubMed ID: 30927209
[TBL] [Abstract][Full Text] [Related]
7. NIH consensus development statement on management of hepatitis B.
Belongia EA; Costa J; Gareen IF; Grem JL; Inadomi JM; Kern ER; McHugh JA; Petersen GM; Rein MF; Sorrell MF; Strader DB; Trotter HT
NIH Consens State Sci Statements; 2008 Oct 22-24; 25(2):1-29. PubMed ID: 18949020
[TBL] [Abstract][Full Text] [Related]
8. Liver safety assessment in special populations (hepatitis B, C, and oncology trials).
Kullak-Ublick GA; Merz M; Griffel L; Kaplowitz N; Watkins PB
Drug Saf; 2014 Nov; 37 Suppl 1(Suppl 1):S57-62. PubMed ID: 25352328
[TBL] [Abstract][Full Text] [Related]
9. Drug-induced liver injury in hospitalized patients with notably elevated alanine aminotransferase.
Xu HM; Chen Y; Xu J; Zhou Q
World J Gastroenterol; 2012 Nov; 18(41):5972-8. PubMed ID: 23139615
[TBL] [Abstract][Full Text] [Related]
10. Drug-induced liver injury.
Leise MD; Poterucha JJ; Talwalkar JA
Mayo Clin Proc; 2014 Jan; 89(1):95-106. PubMed ID: 24388027
[TBL] [Abstract][Full Text] [Related]
11. Indian National Association for the Study of the Liver Consensus Statement on Acute Liver Failure (Part 1): Epidemiology, Pathogenesis, Presentation and Prognosis.
Anand AC; Nandi B; Acharya SK; Arora A; Babu S; Batra Y; Chawla YK; Chowdhury A; Chaoudhuri A; Eapen EC; Devarbhavi H; Dhiman R; Datta Gupta S; Duseja A; Jothimani D; Kapoor D; Kar P; Khuroo MS; Kumar A; Madan K; Mallick B; Maiwall R; Mohan N; Nagral A; Nath P; Panigrahi SC; Pawar A; Philips CA; Prahraj D; Puri P; Rastogi A; Saraswat VA; Saigal S; Shalimar ; Shukla A; Singh SP; Verghese T; Wadhawan M;
J Clin Exp Hepatol; 2020; 10(4):339-376. PubMed ID: 32655238
[TBL] [Abstract][Full Text] [Related]
12. Best practices for detection, assessment and management of suspected immune-mediated liver injury caused by immune checkpoint inhibitors during drug development.
Regev A; Avigan MI; Kiazand A; Vierling JM; Lewis JH; Omokaro SO; Di Bisceglie AM; Fontana RJ; Bonkovsky HL; Freston JW; Uetrecht JP; Miller ED; Pehlivanov ND; Haque SA; Harrison MJ; Kullak-Ublick GA; Li H; Patel NN; Patwardhan M; Price KD; Watkins PB; Chalasani NP
J Autoimmun; 2020 Nov; 114():102514. PubMed ID: 32768244
[TBL] [Abstract][Full Text] [Related]
13. Ratio of serum aspartate to alanine aminotransferase in chronic hepatitis. Relationship to cirrhosis.
Williams AL; Hoofnagle JH
Gastroenterology; 1988 Sep; 95(3):734-9. PubMed ID: 3135226
[TBL] [Abstract][Full Text] [Related]
14. Accuracy of international guidelines for identifying significant fibrosis in hepatitis B e antigen--negative patients with chronic hepatitis.
Sanai FM; Babatin MA; Bzeizi KI; Alsohaibani F; Al-Hamoudi W; Alsaad KO; Al Mana H; Handoo FA; Al-Ashgar H; Alghamdi H; Ibrahim A; Aljumah A; Alalwan A; Altraif IH; Al-Hussaini H; Myers RP; Abdo AA
Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1493-1499.e2. PubMed ID: 23811251
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis C and not Hepatitis B virus is a risk factor for anti-tuberculosis drug induced liver injury.
Kim WS; Lee SS; Lee CM; Kim HJ; Ha CY; Kim HJ; Kim TH; Jung WT; Lee OJ; Hong JW; You HS; Cho HC
BMC Infect Dis; 2016 Feb; 16():50. PubMed ID: 26833347
[TBL] [Abstract][Full Text] [Related]
16. Liver biopsy for assessment of suspected drug-induced liver injury in metabolic dysfunction-associated steatohepatitis clinical trials: Expert consensus from the Liver Forum.
Palmer M; Kleiner DE; Goodman Z; Brunt E; Avigan MI; Regev A; Hayashi PH; Lewis JH; Mehta R; Harrison SA; Siciliano M; McWherter CA; Vuppalanchi R; Behling C; Miller V; Chalasani N; Sanyal AJ
Aliment Pharmacol Ther; 2024 Jan; 59(2):201-216. PubMed ID: 37877759
[TBL] [Abstract][Full Text] [Related]
17. What are the best reference values for a normal serum alanine transaminase activity (ALT)? Impact on the presumed prevalence of drug induced liver injury (DILI).
M'Kada H; Munteanu M; Perazzo H; Ngo Y; Ramanujam N; Imbert-Bismut F; Ratziu V; Bonnefont-Rousselot D; Souberbielle B; Schuppe-Koistinen I; Poynard T;
Regul Toxicol Pharmacol; 2011 Aug; 60(3):290-5. PubMed ID: 21539883
[TBL] [Abstract][Full Text] [Related]
18. Erlotinib-induced Hepatotoxicity-Clinical Presentation and Successful Management: A Case Report.
Arora AK
J Clin Exp Hepatol; 2011 Jun; 1(1):38-40. PubMed ID: 25755309
[TBL] [Abstract][Full Text] [Related]
19. Use of Hy's law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injury.
Robles-Diaz M; Lucena MI; Kaplowitz N; Stephens C; Medina-Cáliz I; González-Jimenez A; Ulzurrun E; Gonzalez AF; Fernandez MC; Romero-Gómez M; Jimenez-Perez M; Bruguera M; Prieto M; Bessone F; Hernandez N; Arrese M; Andrade RJ; ; ;
Gastroenterology; 2014 Jul; 147(1):109-118.e5. PubMed ID: 24704526
[TBL] [Abstract][Full Text] [Related]
20. Antituberculosis drug-induced liver injury in chronic hepatitis and cirrhosis.
Park WB; Kim W; Lee KL; Yim JJ; Kim M; Jung YJ; Kim NJ; Kim DH; Kim YJ; Yoon JH; Oh MD; Lee HS
J Infect; 2010 Oct; 61(4):323-9. PubMed ID: 20670648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
